Pieris Pharmaceuticals (NASDAQ: PIRS) is one of 286 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Pieris Pharmaceuticals to related businesses based on the strength of its valuation, dividends, analyst recommendations, institutional ownership, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and recommmendations for Pieris Pharmaceuticals and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 3 0 3.00
Pieris Pharmaceuticals Competitors 882 3268 11758 235 2.70

Pieris Pharmaceuticals presently has a consensus target price of $9.00, indicating a potential upside of 22.62%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.15%. Given Pieris Pharmaceuticals’ competitors higher possible upside, analysts plainly believe Pieris Pharmaceuticals has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares Pieris Pharmaceuticals and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pieris Pharmaceuticals $5.83 million -$22.79 million -10.05
Pieris Pharmaceuticals Competitors $284.49 million $34.10 million 69.22

Pieris Pharmaceuticals’ competitors have higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Pieris Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -321.83% -221.93% -42.02%
Pieris Pharmaceuticals Competitors -5,246.05% -215.56% -39.08%

Risk & Volatility

Pieris Pharmaceuticals has a beta of -76.07, meaning that its stock price is 7,707% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals’ competitors have a beta of 7.99, meaning that their average stock price is 699% more volatile than the S&P 500.

Insider & Institutional Ownership

50.5% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.1% of Pieris Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Pieris Pharmaceuticals competitors beat Pieris Pharmaceuticals on 9 of the 13 factors compared.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.